Specified Drug Use-Results Survey on "long-term use for Nouriast Tablet "

Specified Drug Use-Results Survey on "long-term use for Nouriast Tablet " - Specified Drug Use-Results Survey on "long-term use for Nouriast Tablet "

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030014

Enrollment

1000

Registered

2017-12-01

Start date

2013-05-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Parkinson's disease patients who were treated with Nouriast Tablets for the first time to improve the wearing-off phenomenon on levodopa-containing preparation therapy.

Exclusion criteria

Exclusion criteria: When the contract is not concluded When the number of contract cases has been reached If the administration start date is out of the contract period For already registered patients When more than 15 days have elapsed from the administration start date Patients used for diseases other than approved efficacy benefits

Design outcomes

Primary

Measure	Time frame
Safety 1.Development of ADR/infectious diseases (type, indication rate, etc.) 2.Investigation of factors considered to affect safety 3.Status of serious adverse events Effectiveness 1.Effective rate 2.Examination of factors considered to affect the effectiveness	—

Countries

Japan

Contacts

Public ContactMasaki Fujita

Kyowa Hakko Kirin Co., Ltd. PV Operation Department ,Pharmacovigilance and Quality Assurance Division

masaki.fujita@kyowa-kirin.co.jp03-5205-7233

Outcome results